McKesson Corporation MCK witnessed strong momentum in the year-to-date period. Shares of the company rallied 34.1% compared with 2.9% growth of the industryin the same period. The S&P 500 ...
We are saving more lives and pets are home with their families much, much faster. For Mars, that is the best metric by which we can measure our success.” Ontada, part of McKesson Corp., is an oncology ...
McKesson (NYSE:MCK) and Oracle (NYSE:ORCL) are among the finalists seeking to acquire electronic medical records company Veradigm (OTC:MDRX), Axios reported Sunday, citing sources. According to ...
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% ...
Shares of McKesson climbed after the drug distributor raised its fiscal-year guidance and reported strong sales growth during its fiscal second quarter. The stock was up 11%, at $610.99 ...